

Florian Ewald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/450372/publications.pdf>

Version: 2024-02-01

14
papers

463
citations

933447

10
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

1040
citing authors

#	ARTICLE	IF	CITATIONS
1	Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. <i>Glycobiology</i> , 2021, , .	2.5	6
2	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. <i>Biomedicines</i> , 2020, 8, 215.	3.2	2
3	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 649-656.	3.3	4
4	Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1548.	4.1	15
5	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. <i>BMC Cancer</i> , 2017, 17, 60.	2.6	24
6	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	1.8	58
7	Associating liver partition and portal vein ligation for staged hepatectomy: From technical evolution to oncological benefit. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 124.	1.5	18
8	Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4. <i>PLoS ONE</i> , 2016, 11, e0146370.	2.5	61
9	Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2015, 6, 1195-1205.	2.5	34
10	COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. <i>Molecular Cancer</i> , 2015, 14, 109.	19.2	89
11	Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. <i>Cellular Signalling</i> , 2015, 27, 2191-2200.	3.6	3
12	ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6117-6126.	7.0	28
13	Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. <i>Investigational New Drugs</i> , 2014, 32, 1144-1154.	2.6	50
14	Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. <i>International Journal of Cancer</i> , 2013, 133, 2065-2076.	5.1	71